Carcinoma of the Stomach
Histopathology Reporting Guide

Family/Last name
Given name(s)
Patient identifiers
Date of birth DD – MM – YYYY
Date of request DD – MM – YYYY
Accession/Laboratory number

Elements in **black text** are **CORE**. Elements in **grey text** are **NON-CORE**.

- Elements in **black text** are **CORE**. Elements in **grey text** are **NON-CORE**.
- Indicates multi-select values
- Indicates single select values

**CLINICAL INFORMATION** (select all that apply)

- Information not provided
- Relevant biopsy results, specify

- Previous diagnosis and treatment for gastric cancer, specify

- Endoscopic location of the tumour, specify

- Clinical staging, specify level of involvement, distant metastases

- Previous partial gastrectomy procedure, specify

- History of chronic gastritis, specify

- Other, specify

**NEOADJUVANT THERAPY**

- Information not provided
- Not administered
- Administered, describe

**OPERATIVE PROCEDURE**

- Not specified
- Gastrectomy
  - Sub-total
  - Total
- Oesophagogastrectomy
- Other, specify

**SPECIMEN DIMENSIONS**

- Length of stomach greater curve mm
- Length of stomach lesser curve mm
- Length of oesophagus mm
- Length of duodenum mm

**TUMOUR FOCALITY**

- Unifocal
- Multifocal, specify number of tumours in specimen

- Cannot be assessed, specify

* If multiple primary tumours are present, separate datasets should be used to record this and all following elements for each primary tumour.
### Carcinoma of the Stomach

#### TUMOUR SITE

- Not specified
- Region
  - Upper third
  - Middle third
  - Distal third
- Curvature
  - Greater
  - Lesser
- Wall
  - Anterior
  - Posterior
- Other, specify

#### TUMOUR DIMENSIONS

- Maximum tumour dimension
  - **mm**
- Additional dimensions
  - **mm** × **mm**
- Cannot be assessed, specify

#### MACROSCOPIC TUMOUR TYPE

- Not applicable
- Cannot be assessed
- Polypoid mass (Borrmann type I)
- Ulcerative (Borrmann type II)
- Infiltrative ulcerative (Borrmann type III)
- Diffuse infiltrative (Borrmann type IV)
- Other, specify

#### HISTOLOGICAL TUMOUR TYPE

**World Health Organization (WHO) Classification**

- Not applicable
- Tubular adenocarcinoma
- Papillary adenocarcinoma
- Mucinous adenocarcinoma
- Poorly cohesive carcinoma, including signet-ring cell carcinoma and other subtypes
- Mixed adenocarcinoma
- Other histological type/subtype, specify

**Lauren Classification**

- Intestinal
- Diffuse
- Mixed
- Indeterminate

#### HISTOLOGICAL TUMOUR GRADE

- Not applicable
- Cannot be assessed
- Low grade (well and moderately differentiated)
- High grade (poorly differentiated)
- Other, specify

#### EXTENT OF INVASION

- Cannot be assessed
- No evidence of primary tumour
- Carcinoma in situ (intraepithelial tumour without invasion of the lamina propria, high grade dysplasia)
- Invasion into the lamina propria
- Invasion into the muscularis mucosae
- Invasion into the submucosa
- Invasion into the muscularis propria
- Invasion into the subserosal connective tissue (without invasion of the visceral peritoneum or adjacent structures)
- Invasion into the serosa (visceral peritoneum)
- Invasion into adjacent structure(s)/organ(s), specify

#### LYMPHOVASCULAR INVASION

- Not identified
- Present

#### PERINEURAL INVASION

- Not identified
- Present

#### RESPONSE TO NEOADJUVANT THERAPY

- No neoadjuvant treatment
- Complete response - no viable cancer cells (score 0)
- Near complete response - single cells or rare small groups of cancer cells (score 1)
- Partial response - residual cancer with evident tumour regression, but more than single cells or rare groups of cancer cells (score 2)
- Poor or no response - extensive residual cancer with no evident tumour regression (score 3)
- Cannot be assessed, specify
Carcinoma of the Stomach

MARGIN STATUS

Invasive carcinoma

- Cannot be assessed
- Not involved
- Involved (select all that apply)
  - Distal
  - Proximal
  - Circumferential/Radial

Dysplasia

- Cannot be assessed
- Not involved
- Involved (select all that apply)
  - Carcinoma in situ/high grade dysplasia
  - Low grade
- Specify margin (select all that apply)
  - Distal
  - Proximal
  - Other, specify

LYMPH NODE STATUS

- Cannot be assessed
- No nodes submitted or found
- Number of lymph nodes examined
- Not involved
- Involved
  - Number of involved lymph nodes

ANCILLARY STUDIES

For neuroendocrine neoplasms only

- Not applicable
- Neuroendocrine markers (chromogranin A, synaptophysin, other), specify test(s) performed and result(s) if available

AND

- Ki-67 proliferation index

Other gastric carcinomas

- Not performed
- Performed (select all that apply)
  - HER2 testing performed, record result(s)
  - Microsatellite instability (MSI)/Mismatch repair (MMR) testing, record result(s)
  - Epstein-Barr virus (EBV)-status (e.g., EBV encoded RNA (EBER) in situ hybridisation), record result(s)

- Other, specify test(s) and result(s)

HISTOLOGICALLY CONFIRMED DISTANT METASTASES

- Not identified
- Present, specify site(s)

COEXISTENT PATHOLOGY (select all that apply)

- None identified
- Helicobacter gastritis
- Autoimmune gastritis
- Reactive gastritis
- Intestinal metaplasia
- Gastric polyps, specify

- Dysplasia
  - Low grade
  - High grade
  - Indeterminate
  - Synchronous carcinoma(s), specify

- Other, specify
## Carcinoma of the Stomach

### PATHOLOGICAL STAGING (UICC TNM 8th edition)

**TNM Descriptors** (only if applicable) (select all that apply)
- **m** - multiple primary tumours
- **r** - recurrent
- **y** - post-therapy

**Primary tumour (pT)**
- **TX** Primary tumour cannot be assessed
- **T0** No evidence of primary tumour
- **Tis** Carcinoma in situ: intraepithelial tumour without invasion of the lamina propria, high grade dysplasia
- **T1** Tumour invades lamina propria, muscularis mucosae, or submucosa
  - **T1a** Tumour invades lamina propria or muscularis mucosae
  - **T1b** Tumour invades submucosa
- **T2** Tumour invades muscularis propria
- **T3** Tumour invades subserosa
- **T4** Tumour perforates serosa (visceral peritoneum) or invades adjacent structures\(^{c,d,e}\)
  - **T4a** Tumour perforates serosa
  - **T4b** Tumour invades adjacent structures\(^{c,d}\)

**Regional lymph nodes (pN)**
- **NX** Regional lymph node(s) cannot be assessed
- **N0** No regional lymph node metastasis
- **N1** Metastasis in 1 to 2 regional lymph nodes
- **N2** Metastasis in 3 to 6 regional lymph nodes
- **N3** Metastasis in 7 or more regional lymph nodes
  - **N3a** Metastasis in 7 to 15 regional lymph nodes
  - **N3b** Metastasis in 16 or more regional lymph nodes


\(^{c}\) The adjacent structures of the stomach are the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum.

\(^{d}\) Intramural extension to the duodenum or oesophagus is classified by the depth of greatest invasion in any of these sites including stomach.

\(^{e}\) Tumour that extends into gastrocolic or gastrohepatic ligaments or into greater or lesser omentum, without perforation of visceral peritoneum, is T3.